Cure Today5d
FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
Cancer Therapy Advisor4d
Kisqali Approved for HR+, HER2- Early Breast Cancer
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib ... This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data ...
The American Journal of Managed Care5d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Medpage Today on MSN4d
FDA Expands Approval of Ribociclib to Early Breast Cancer
The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
MedPage Today5d
FDA Expands Approval of Ribociclib to Early Breast Cancer
The drug joins abemaciclib (Verzenio ... FDA also approved a ribociclib and letrozole co-pack (Kisqali Femara Co-Pack) for the same indication. NATALEE included patients either with lymph node ...